Aurobindo Pharma Launches ADQUEY in US, Establishes Dermatology Business

Aurobindo Pharma's subsidiary, Acrotech Biopharma, has launched ADQUEY™ (difamilast 1%) ointment in the U.S. market. This non-steroidal topical treatment is for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 years and older. The launch signifies Acrotech's entry into the U.S. dermatology sector and is supported by the establishment of a dedicated dermatology business unit. The market for this treatment is estimated at US$ 1.3 billion. ADQUEY was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech for U.S. commercialization. This move aligns with Acrotech's strategy to expand its portfolio of innovative medicines.